Study

EORTC-90101

Cross-tumoral Phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET ("CREATE")

Study documentation Back to result

Trial Status

Closed to Patient Entry

Dates

Date of activation: 27-Aug-2012
Date Step1 close: 04-Jul-2017
Date Step2 close: 04-Jul-2017

Data management at EORTC

Yes

Design

Phase 2
Randomized open label

Targeted Sample size

EORTC Groups: 582 - All Groups: 582

Treatment

Drug
Crizotinib

Study Staff

  • Patrick Schoeffski (Study Coordinator), U.Z. Leuven - Campus Gasthuisberg, Leuven
  • Lieve Dirix (Senior Clinical Operations Manager), EORTC Headquarters, Brussels
  • Sandrine Marreaud (Clinical Research Physician), EORTC Headquarters, Brussels
  • Sara Meloen (Pharmacovigilance Manager), EORTC Headquarters, Brussels
  • Axelle Nzokirantevye (Data Manager), EORTC Headquarters, Brussels
  • Xiao Mang Zhou (Junior RAM), EORTC Headquarters, Brussels

Type of cancer

  • Non Hodgkins Lymphoma
  • Kidney
  • Soft Tissue and Bone Sarcoma

Participating groups

Recruiting centers

  • Centre Georges-Francois-Leclerc (DIJON CEDEX, France)
  • Centre Leon Berard (Lyon, France)
  • Gustave Roussy (VILLEJUIF CEDEX, France)
  • Helios Klinikum Bad Saarow (Bad Saarow-Pieskow, Germany)
  • Hopital de La Timone (APHM) (MARSEILLE, France)
  • IRCCS - Fondazione Istituto Nazionale dei Tumori (Milano, Italy)
  • Institut Bergonie (Bordeaux, France)
  • Institut Jules Bordet (Anderlecht, Belgium)
  • Leeds Teaching Hospitals NHS Trust - St. James's University Hospital (Leeds, United Kingdom)
  • Leiden University Medical Centre (Leiden, Netherlands)
  • Ludwig-Maximilians-Universitaet Muenchen - Campus Grosshadern (Muenchen, Germany)
  • Maria Sklodowska-Curie National Research Institute of Oncology (Warsaw, Poland)
  • Medizinische Hochschule Hannover (Hannover, Germany)
  • Narodny Onkologicky Ustav - Bratislava (Bratislava, Slovakia)
  • Nottingham University Hospitals NHS Trust - City Hospital (Nottingham, United Kingdom)
  • Oslo University Hospital - Radiumhospitalet (Oslo, Norway)
  • Radboud University Medical Center Nijmegen (Nijmegen, Netherlands)
  • The Christie NHS Foundation Trust (Manchester, United Kingdom)
  • The Institute Of Oncology (Ljubljana, Slovenia)
  • U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium)
  • UniversitaetsMedizin Mannheim (Mannheim, Germany)
  • Universitaetsklinikum - Essen (Essen, Germany)
  • Universitaetsklinikum Carl Gustav Carus (TUD) (Dresden, Germany)
  • University College Hospital (London, United Kingdom)

Protocol summary

http://clinicaltrials.gov/study/NCT01524926

NCT number

NCT01524926

EudraCT

2011-001988-52